Based on the provided paper content, I will answer each question systematically.

"""
Question: 1101

Evidence: "Here, we explored how preexisting NRTI resistance mutations affect the development of EFdA resistance. We selected viruses resistant to EFdA by serial passage of HIV-1 that was either WT or resistant to TFV (K65R), 3TC/FTC (M184V), or AZT (D67N/K70R/T215F/K219Q)." "Serial passages were initiated by infecting MT-2 cells with WT (xxLAI), K65R, M184V, or D67N/K70R/T215F/K219Q stock virus in the presence of EFdA and monitored as described in Materials and Methods."

Rationale: The paper describes conducting new serial passage experiments to study EFdA resistance development, which constitutes previously unpublished data generated by the authors.

Answer: Yes
"""

"""
Question: 1102

Evidence: "Clonal sequencing confirmed the identity of the P 0 stock viruses. Similar sequencing was carried out on clones from various passages to identify any changes in RT that may have arisen during replication in the presence of EFdA." "Mutation sequences for BankIt2501100 Seq1 to Seq14 have been deposited in GenBank under accession no. OK263149 to OK263162."

Rationale: The paper explicitly mentions sequencing HIV reverse transcriptase genes from various passages and depositing these sequences in GenBank, confirming that HIV sequences are reported.

Answer: Yes
"""

"""
Question: 1103

Evidence: "We selected viruses resistant to EFdA by serial passage of HIV-1 that was either WT or resistant to TFV (K65R), 3TC/FTC (M184V), or AZT (D67N/K70R/T215F/K219Q)." "Serial passages were initiated by infecting MT-2 cells with WT (xxLAI), K65R, M184V, or D67N/K70R/T215F/K219Q stock virus in the presence of EFdA and monitored as described in Materials and Methods."

Rationale: The paper extensively describes in vitro passage experiments conducted to select for EFdA-resistant viruses, with detailed methodology provided.

Answer: Yes
"""

"""
Question: 1104

Evidence: "To evaluate the degree of resistance selected in the passaging experiments, sensitivity to EFdA was determined for virus supernatants from passage 6 (P 6 ) onward." "Dose response to individual mutants. All individual mutations were cloned into pNL4.3 using Emory's Cloning Core. After each virus was generated as described above, TZM-GFP cells were plated at 10,000 cells/well in a 96-well plate and with serially diluted EFdA, TDF, or FTC starting at 100 nM (for EFdA) or 10 μM (TDF and FTC)."

Rationale: The paper contains multiple sections describing antiretroviral susceptibility testing using dose-response curves for EFdA, TDF, and FTC against various HIV mutants.

Answer: Yes
"""

"""
Question: 2101

Evidence: "Mutation sequences for BankIt2501100 Seq1 to Seq14 have been deposited in GenBank under accession no. OK263149 to OK263162."

Rationale: The paper explicitly states that mutation sequences have been deposited in GenBank and provides the specific accession numbers.

Answer: Yes
"""

"""
Question: 2102

Evidence: "Mutation sequences for BankIt2501100 Seq1 to Seq14 have been deposited in GenBank under accession no. OK263149 to OK263162."

Rationale: The paper reports GenBank accession numbers for sequences generated through their experimental work (serial passage and mutation analysis), which are not standard laboratory isolates but rather experimentally derived variants.

Answer: Yes
"""

"""
Question: 2103

Evidence: "Mutation sequences for BankIt2501100 Seq1 to Seq14 have been deposited in GenBank under accession no. OK263149 to OK263162."

Rationale: The paper specifically lists the GenBank accession numbers as OK263149 to OK263162 for the 14 sequences deposited.

Answer: OK263149 to OK263162
"""

"""
Question: 2202

Evidence: "Table 1 summarizes the data for P 6 and P 9 isolates for all parental viruses, as well as viruses from P 6 , P 9 , and P 10 for K65R." "During the passages that started with M184V, the connection domain mutation R358K appeared and became increasingly dominant as passaging progressed."

Rationale: Table 1 and the results section provide detailed lists of mutations found in individual sequenced HIV isolates from various passages, showing the proportion of sequences with specific mutations.

Answer: Yes
"""

"""
Question: 2301

Evidence: "EFdA is highly potent against both wild-type (WT) HIV-1, HIV-2, and NRTI-resistant strains (34, 40–42)." "Serial passages were initiated by infecting MT-2 cells with WT (xxLAI), K65R, M184V, or D67N/K70R/T215F/K219Q stock virus in the presence of EFdA."

Rationale: The paper specifically mentions working with HIV-1 strains throughout the experiments, with references to HIV-2 only in the context of general EFdA potency.

Answer: HIV-1
"""

"""
Question: 2302

Evidence: No evidence found in the paper content about specific subtypes of the sequenced viruses.

Rationale: The paper describes using laboratory strains (xxLAI, NL4-3) and their mutants, but does not specify HIV subtypes for the sequenced viruses.

Answer: NA
"""

"""
Question: 2303

Evidence: "These primers anneal to the 3′ end of gag and the 5′ end of integrase, respectively, and generate a 2,127-bp product spanning the full length of the reverse transcriptase gene." "Clonal sequencing of full-length reverse transcriptase gene PCR products."

Rationale: The methodology section clearly states that sequencing was performed on the full-length reverse transcriptase (RT) gene.

Answer: Reverse transcriptase (RT) gene
"""

"""
Question: 2304

Evidence: "These primers anneal to the 3′ end of gag and the 5′ end of integrase, respectively, and generate a 2,127-bp product spanning the full length of the reverse transcriptase gene." "Clonal sequencing of full-length reverse transcriptase gene PCR products."

Rationale: The paper explicitly states that sequencing covered the full-length reverse transcriptase gene, which is part of the pol region.

Answer: Yes
"""

"""
Question: 2401

Evidence: No evidence found in the paper content about geographic regions or countries of origin for the sequences.

Rationale: The study used laboratory-derived HIV strains and their mutants, with no mention of geographic origin for the sequences.

Answer: NA
"""

"""
Question: 2402

Evidence: No evidence found in the paper content about years when samples were obtained.

Rationale: The paper describes experimental work with laboratory strains but does not specify when the original samples or sequences were obtained.

Answer: NA
"""

"""
Question: 2502

Evidence: "PCR products were separated by electrophoresis on a 1% agarose gel, and the 2,127-bp band was harvested using a QIAquick gel extraction kit (Qiagen). The concentration of DNA was determined by spectrophotometry, and 500 ng of sample was submitted to ACGT, Inc. (Wheeling, IL), for full-length, double-stranded population sequencing."

Rationale: The methodology describes conventional Sanger sequencing techniques including PCR, gel electrophoresis, and population sequencing without mentioning next-generation sequencing technologies.

Answer: Yes
"""

"""
Question: 2503

Evidence: No evidence found in the paper content about use of NGS technology.

Rationale: The sequencing methodology described uses traditional Sanger sequencing approaches without any mention of next-generation sequencing technologies.

Answer: No
"""

"""
Question: 2504

Evidence: "Approximately 105 ng of full-length PCR product was ligated into the pGEM-T vector system (Promega, Madison, WI) at a 3:1 insert/vector molar ratio and incubated overnight at 4°C. Ligations were transformed into MAX Efficiency DH5α competent cells (Invitrogen) by heat shock. Blue-white screening was used to select clones with successful ligations, and plasmids containing the full-length reverse transcriptase gene were isolated with a QIAprep Spin Miniprep kit (Qiagen)."

Rationale: The paper explicitly describes cloning PCR products into plasmids prior to sequencing.

Answer: Yes
"""

"""
Question: 2505

Evidence: No evidence found in the paper content about single genome sequencing.

Rationale: While the paper describes clonal sequencing, it does not specifically mention single genome sequencing methodology.

Answer: No
"""

"""
Question: 2506

Evidence: "Approximately 105 ng of full-length PCR product was ligated into the pGEM-T vector system (Promega, Madison, WI) at a 3:1 insert/vector molar ratio and incubated overnight at 4°C. Ligations were transformed into MAX Efficiency DH5α competent cells (Invitrogen) by heat shock."

Rationale: The methodology section clearly describes molecular cloning of PCR products into plasmid vectors for sequencing.

Answer: Yes
"""

"""
Question: 2601

Evidence: No evidence found in the paper content about plasma HIV sequencing.

Rationale: The paper describes sequencing of viruses from cell culture supernatants from in vitro experiments, not from patient plasma samples.

Answer: No
"""

"""
Question: 2602

Evidence: No evidence found in the paper content about PBMC HIV sequencing.

Rationale: The paper describes sequencing of viruses from cell culture experiments using MT-2 and other cell lines, not from patient PBMCs.

Answer: No
"""

"""
Question: 2603

Evidence: No evidence found in the paper content about plasma virus sequencing.

Rationale: The study used cell culture-derived viruses, not patient plasma samples.

Answer: 0
"""

"""
Question: 2604

Evidence: No evidence found in the paper content about PBMC virus sequencing.

Rationale: The study used cell culture-derived viruses, not patient PBMC samples.

Answer: 0
"""

"""
Question: 2605

Evidence: "Serial passages were initiated by infecting MT-2 cells with WT (xxLAI), K65R, M184V, or D67N/K70R/T215F/K219Q stock virus in the presence of EFdA and monitored as described in Materials and Methods." "At the end of the passaging, all EFdA-selected viruses, regardless the initial strain or number of passages, induced ≥75% syncytium formation in untreated MT-2 cells within 7 days of infection, indicating that they had retained replication fitness."

Rationale: The paper describes active HIV replication in cell culture experiments, but these are not from individuals with natural HIV infection.

Answer: No
"""

"""
Question: 2606

Evidence: No evidence found in the paper content about proviral DNA reservoir sequencing.

Rationale: The paper describes sequencing of replication-competent viruses from cell culture, not proviral DNA from infected individuals.

Answer: No
"""

"""
Question: 2701

Evidence: No evidence found in the paper content about samples from infants or children.

Rationale: The study used laboratory HIV strains and cell cultures, with no mention of human subjects, infants, or children.

Answer: No
"""

"""
Question: 2702

Evidence: No evidence found in the paper content about individuals in clinical trials.

Rationale: The paper describes in vitro experiments with cell cultures and recombinant viruses, not human subjects in clinical trials.

Answer: No
"""

"""
Question: 2703

Evidence: No evidence found in the paper content about individuals in clinical trials.

Rationale: The study is entirely based on in vitro experiments without human subjects.

Answer: No
"""

"""
Question: 3101

Evidence: No evidence found in the paper content about individuals undergoing HIV sequencing.

Rationale: The paper describes sequencing of laboratory-derived viruses from cell culture experiments, not sequencing from human individuals.

Answer: 0
"""

"""
Question: 3102

Evidence: No evidence found in the paper content about individuals undergoing HIV sequencing.

Rationale: The study used laboratory viruses and cell cultures, not human subjects.

Answer: No
"""

"""
Question: 4101

Evidence: No evidence found in the paper content about ART-naive individuals.

Rationale: The study used laboratory HIV strains in cell culture experiments, not samples from ART-naive individuals.

Answer: No
"""

"""
Question: 4102

Evidence: No evidence found in the paper content about ART-experienced individuals.

Rationale: The study used laboratory HIV strains with engineered resistance mutations, not samples from ART-experienced individuals.

Answer: No
"""

"""
Question: 4103

Evidence: No evidence found in the paper content about ART-naive or ART-experienced individuals.

Rationale: The paper describes in vitro experiments with laboratory viruses, not human subjects with ART history.

Answer: No
"""

"""
Question: 4104

Evidence: No evidence found in the paper content about ART-naive individuals.

Rationale: The study did not involve human subjects with ART history.

Answer: 0
"""

"""
Question: 4105

Evidence: No evidence found in the paper content about ART history information.

Rationale: The paper describes in vitro experiments with laboratory viruses, not human subjects with ART history.

Answer: No
"""

"""
Question: 4201

Evidence: No evidence found in the paper content about transmitted HIV drug resistance.

Rationale: The study focused on in vitro selection of resistance mutations, not surveillance of transmitted drug resistance in populations.

Answer: No
"""

"""
Question: 4202

Evidence: No evidence found in the paper content about pretreatment HIV drug resistance.

Rationale: The study focused on in vitro selection of resistance mutations, not pretreatment drug resistance in clinical samples.

Answer: No
"""

"""
Question: 4301

Evidence: No evidence found in the paper content about drug classes received by individuals.

Rationale: The study did not involve human subjects receiving ART.

Answer: NA
"""

"""
Question: 4302

Evidence: No evidence found in the paper content about individuals receiving integrase inhibitors.

Rationale: The study did not involve human subjects receiving ART.

Answer: No
"""

"""
Question: 4303

Evidence: No evidence found in the paper content about individuals receiving protease inhibitors.

Rationale: The study did not involve human subjects receiving ART.

Answer: No
"""

"""
Question: 4304

Evidence: No evidence found in the paper content about individuals receiving ART.

Rationale: The study did not involve human subjects receiving ART.

Answer: NA
"""

"""
Question: 4305

Evidence: No evidence found in the paper content about INSTI-naive individuals.

Rationale: The study did not involve human subjects.

Answer: NA
"""

"""
Question: 4403

Evidence: No evidence found in the paper content about individuals receiving multiple ART regimens.

Rationale: The study did not involve human subjects receiving ART.

Answer: 0
"""

"""
Question: 4404

Evidence: No evidence found in the paper content about individuals receiving multiple ART regimens.

Rationale: The study did not involve human subjects receiving ART.

Answer: 0
"""

"""
Question: 4405

Evidence: No evidence found in the paper content about individuals receiving ART regimens.

Rationale: The study did not involve human subjects receiving ART.

Answer: NA
"""

"""
Question: 4406

Evidence: No evidence found in the paper content about individuals receiving one ART regimen.

Rationale: The study did not involve human subjects receiving ART.

Answer: No
"""

"""
Question: 4501

Evidence: No evidence found in the paper content about individuals receiving dolutegravir.

Rationale: The study did not involve human subjects receiving specific ART drugs.

Answer: 0
"""

"""
Question: 4502

Evidence: No evidence found in the paper content about individuals receiving darunavir.

Rationale: The study did not involve human subjects receiving specific ART drugs.

Answer: 0
"""

"""
Question: 5101

Evidence: No evidence found in the paper content about individuals with drug resistance mutations.

Rationale: The study identified resistance mutations in laboratory viruses through in vitro experiments, not in human individuals.

Answer: 0
"""

"""
Question: 5102

Evidence: No evidence found in the paper content about INSTI-resistance mutations.

Rationale: The paper focuses on NRTI resistance mutations (specifically EFdA resistance) and does not mention INSTI-resistance mutations.

Answer: 0
"""

"""
Question: 5103

Evidence: No evidence found in the paper content about individuals with TDF-resistance mutations.

Rationale: The study used laboratory strains with engineered mutations, but did not report individuals with TDF-resistance mutations.

Answer: 0
"""

"""
Question: 5104

Evidence: No evidence found in the paper content about INSTI-resistance mutations.

Rationale: The paper focuses on NRTI resistance and does not report any INSTI-resistance mutations.

Answer: NA
"""

"""
Question: 6101

Evidence: "To determine whether the various EFdA resistance mutations are susceptible to approved drugs such as tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC), we prepared dose-response curves ( Table 2 )." "Dose response to individual mutants. All individual mutations were cloned into pNL4.3 using Emory's Cloning Core. After each virus was generated as described above, TZM-GFP cells were plated at 10,000 cells/well in a 96-well plate and with serially diluted EFdA, TDF, or FTC starting at 100 nM (for EFdA) or 10 μM (TDF and FTC)."

Rationale: The paper describes using dose-response curves in TZM-GFP cells to determine phenotypic susceptibility.

Answer: Dose-response curves in TZM-GFP cells
"""

"""
Question: 6102

Evidence: "The GFP-positive cells were then counted using Cytation 5 (BioTek, Winooski, VT) with Gen5 v3.03 software. EC 50 curves were then determined using Prism 5 (GraphPad) software." "To evaluate the degree of resistance selected in the passaging experiments, sensitivity to EFdA was determined for virus supernatants from passage 6 (P 6 ) onward."

Rationale: The paper explicitly mentions determining EC50 values for various drugs and viruses.

Answer: Yes
"""

"""
Question: 6103

Evidence: "Table 2 EC50 fold change compared to WT (NL4-3)" "M184V was the only individual mutation that conferred ∼8-fold EFdA resistance, consistent with previous reports ( 42 , 57 )."

Rationale: Table 2 specifically reports EC50 fold changes, and the results section discusses fold resistance values.

Answer: Yes
"""

"""
Question: 6104

Evidence: "Dose response to individual mutants. All individual mutations were cloned into pNL4.3 using Emory's Cloning Core. After each virus was generated as described above, TZM-GFP cells were plated at 10,000 cells/well in a 96-well plate and with serially diluted EFdA, TDF, or FTC starting at 100 nM (for"""
Question: 6104

Evidence: "Dose response to individual mutants. All individual mutations were cloned into pNL4.3 using Emory's Cloning Core. After each virus was generated as described above, TZM-GFP cells were plated at 10,000 cells/well in a 96-well plate and with serially diluted EFdA, TDF, or FTC starting at 100 nM (for EFdA) or 10 μM (TDF and FTC)." "The GFP-positive cells were then counted using Cytation 5 (BioTek, Winooski, VT) with Gen5 v3.03 software. EC 50 curves were then determined using Prism 5 (GraphPad) software."

Rationale: The paper describes using TZM-GFP cells with GFP readout to measure infection and determine EC50 values, which is a standard phenotypic susceptibility assay format.

Answer: TZM-GFP cell-based assay with GFP readout
"""

"""
Question: 6105

Evidence: "To determine the effect of mutations on viral fitness, we tested viruses in single-cycle replication assays known as specific infectivity." "There were no statistically significant differences between the specific infectivities of WT, R358K, or A502V. M184V had a reduced specific infectivity compared to WT; it did not appear to be statistically significant under these experimental conditions."

Rationale: The paper explicitly reports on specific infectivity assays, which measure replication capacity of the mutant viruses compared to wild-type.

Answer: Yes
"""

"""
Question: 6106

Evidence: "To determine whether the various EFdA resistance mutations are susceptible to approved drugs such as tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC), we prepared dose-response curves ( Table 2 )." "Dose response to individual mutants. All individual mutations were cloned into pNL4.3 using Emory's Cloning Core. After each virus was generated as described above, TZM-GFP cells were plated at 10,000 cells/well in a 96-well plate and with serially diluted EFdA, TDF, or FTC starting at 100 nM (for EFdA) or 10 μM (TDF and FTC)."

Rationale: The paper clearly states that phenotypic susceptibility testing was performed for EFdA, TDF (tenofovir), and FTC (emtricitabine).

Answer: EFdA, TDF (tenofovir), FTC (emtricitabine)
"""

"""
Question: 7101

Evidence: "Initial K65R, M184V, and D67N/K70R/T215F/K219Q viruses were generated by site-directed mutagenesis on an xxLAI HIV-1 backbone using the QuikChange XL site-directed mutagenesis kit (Agilent Technologies, Inc., Santa Clara, CA) according to the manufacturer's protocols." "All individual mutations were cloned into pNL4.3 using Emory's Cloning Core."

Rationale: The paper explicitly describes using site-directed mutagenesis to create specific HIV mutants for testing.

Answer: Yes
"""

"""
Question: 7102

Evidence: "We selected viruses resistant to EFdA by serial passage of HIV-1 that was either WT or resistant to TFV (K65R), 3TC/FTC (M184V), or AZT (D67N/K70R/T215F/K219Q)." "Serial passages were initiated by infecting MT-2 cells with WT (xxLAI), K65R, M184V, or D67N/K70R/T215F/K219Q stock virus in the presence of EFdA and monitored as described in Materials and Methods."

Rationale: The paper extensively describes in vitro passage experiments to select for EFdA-resistant viruses from various starting strains.

Answer: Yes
"""